Results 291 to 300 of about 787,943 (334)

New cancer breakthrough therapies at the United States Food and Drug Administration

Journal of Hospital Management and Health Policy, 2018
Cancer is an emotive word that strikes fear into many people. This is hardly surprising since premature death due to cancer is the leading cause of mortality in Canada, the United States and many other countries.
openaire   +1 more source

Cancer statistics, 2022

Ca-A Cancer Journal for Clinicians, 2022
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal Dvm   +2 more
exaly  

Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration

American Journal of Gastroenterology, 2000
James G. Kohlroser, J. Mathai, J. Reichheld, B. Banner, H. Bonkovsky   +4 more
semanticscholar   +2 more sources

Cancer statistics, 2023

Ca-A Cancer Journal for Clinicians, 2023
Rebecca L Siegel, Kimberly D Miller, Nikita Sandeep Wagle   +2 more
exaly  

United States Food and Drug Administration requirements for approval of generic drug products.

The Journal of clinical psychiatry, 2001
As generic products become more available for the treatment of psychiatric disorders, clinicians must stay abreast of the U.S. Food and Drug Administration (FDA) requirements for the approval of generic drug products. The FDA declares that pharmaceutical equivalents only are therapeutically equivalent, and pharmacokinetic data are all that is usually ...
openaire   +1 more source

Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use

Pharmacotherapy, 2008
F. Frueh, Shashi Amur, P. Mummaneni, R. Epstein, R. Aubert, Teresa M. DeLuca, R. Verbrugge, G. Burckart, L. Lesko   +8 more
semanticscholar   +1 more source

Cancer statistics, 2020

Ca-A Cancer Journal for Clinicians, 2020
Rebecca L Siegel, Kimberly D Miller
exaly  

Autologous cultured chondrocytes: adverse events reported to the United States Food and Drug Administration.

Journal of Bone and Joint Surgery. American volume, 2006
J. J. Wood, Mark A. Malek, F. Frassica, J. Polder, A. Mohan, E. Bloom, M. Braun, T. Coté   +7 more
semanticscholar   +1 more source

Nonclinical Development of Radiopharmaceuticals: Regulatory Considerations for the United States Food and Drug Administration

2004
In general, the nonclinical studies conducted to support the development of radiopharmaceuticals should be consistent with current International Conference on Harmonization (ICH) Guidelines. The United States Food and Drug Administration (FDA), however, has recognized that certain characteristics of radiopharmaceuticals necessitate an adaptation of the
openaire   +2 more sources

United States Food and Drug Administration TASS Program

Ophthalmology, 2013
openaire   +2 more sources